



Clinical trial results:

Opium tincture against chronic diarrhea - Patients: An investigator initiated, randomized placebo-controlled, clinical trial

Summary

EudraCT number	2020-000396-20
Trial protocol	DK
Global end of trial date	21 December 2023

Results information

Result version number	v1 (current)
This version publication date	04 September 2024
First version publication date	04 September 2024

Trial information

Trial identification

Sponsor protocol code	Dropizol_2020
-----------------------	---------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT05690321
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Aalborg University Hospital
Sponsor organisation address	Mølleparkvej 4, Aalborg, Denmark, 9000
Public contact	Tina Okdahl , Mech-Sense, Aalborg University Hospital, +45 97663520, t.okdahl@rn.dk
Scientific contact	Tina Okdahl , Mech-Sense, Aalborg University Hospital, +45 97663520, t.okdahl@rn.dk

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	01 February 2024
Is this the analysis of the primary completion data?	Yes
Primary completion date	21 December 2023
Global end of trial reached?	Yes
Global end of trial date	21 December 2023
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

Main objective of the trial is to describe the efficacy and safety of opium tincture (Dropizol®, Pharmanovia A/S, Denmark) against chronic diarrhea.

Protection of trial subjects:

Subjects were instructed to report all experienced side effects in a diary, which was monitored throughout the study

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	30 January 2023
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Denmark: 11
Worldwide total number of subjects	11
EEA total number of subjects	11

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	10
From 65 to 84 years	1
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Recruitment was initiated in January 2023 and was finalized in December 2023

Pre-assignment

Screening details:

A medical doctor screened all subjects according to the inclusion and exclusion criteria

Pre-assignment period milestones

Number of subjects started	11
Number of subjects completed	11

Period 1

Period 1 title	Intervention (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Arms

Are arms mutually exclusive?	No
Arm title	Opium tincture

Arm description:

Active intervention

Arm type	Experimental
Investigational medicinal product name	Opium tincture
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral drops, liquid
Routes of administration	Oral use

Dosage and administration details:

The treatment was divided into two phases: up-titration (3 × 5 drops on days 1–3) and end-titration (3 × 10 drops on days 4–6 and 2 × 10 drops on day 7)

Arm title	Placebo
------------------	---------

Arm description:

Placebo intervention

Arm type	Placebo
Investigational medicinal product name	Placebo drops
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral drops, liquid
Routes of administration	Oral use

Dosage and administration details:

The treatment was divided into two phases: up-titration (3 × 5 drops on days 1–3) and end-titration (3 × 10 drops on days 4–6 and 2 × 10 drops on day 7)

Number of subjects in period 1	Opium tincture	Placebo
Started	11	11
Completed	11	11

Baseline characteristics

Reporting groups

Reporting group title	Intervention
-----------------------	--------------

Reporting group description: -

Reporting group values	Intervention	Total	
Number of subjects	11	11	
Age categorical			
Units: Subjects			
In utero		0	
Preterm newborn infants (gestational age < 37 wks)		0	
Newborns (0-27 days)		0	
Infants and toddlers (28 days-23 months)		0	
Children (2-11 years)		0	
Adolescents (12-17 years)		0	
Adults (18-64 years)		0	
From 65-84 years		0	
85 years and over		0	
Age continuous			
Units: years			
arithmetic mean	44.9		
standard deviation	± 17.3	-	
Gender categorical			
Units: Subjects			
Female	6	6	
Male	5	5	

End points

End points reporting groups

Reporting group title	Opium tincture
Reporting group description:	
Active intervention	
Reporting group title	Placebo
Reporting group description:	
Placebo intervention	

Primary: Mean number of daily bowel movements

End point title	Mean number of daily bowel movements
End point description:	
End point type	Primary
End point timeframe:	
Comparison of mean number of bowel movements per day during active and placebo treatment	

End point values	Opium tincture	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	11	11		
Units: Number				
median (inter-quartile range (Q1-Q3))	2.3 (1.7 to 2.3)	3.0 (1.7 to 4.7)		

Statistical analyses

Statistical analysis title	Bowel movement frequency between treatments
Statistical analysis description:	
Bowel movement frequency between treatments was compared using a repeated mixed model with days and treatments (place/opium tincture) as factors	
Comparison groups	Opium tincture v Placebo
Number of subjects included in analysis	22
Analysis specification	Pre-specified
Analysis type	equivalence
P-value	= 0.002
Method	Mixed models analysis

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events were collected from the time of inclusion to 5 days after study end

Adverse event reporting additional description:

Adverse events were noted by subjects in a diary, and study personel also asked about adverse events at vistic and follow-up calls

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	None
-----------------	------

Dictionary version	0
--------------------	---

Reporting groups

Reporting group title	During active treatment
-----------------------	-------------------------

Reporting group description: -

Reporting group title	During placebo treatment
-----------------------	--------------------------

Reporting group description: -

Serious adverse events	During active treatment	During placebo treatment	
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Gastrointestinal disorders			
Hospitalization due to abdominal pain			
subjects affected / exposed	1 / 11 (9.09%)	0 / 11 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	During active treatment	During placebo treatment	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	8 / 11 (72.73%)	5 / 11 (45.45%)	
Nervous system disorders			
Headache			
subjects affected / exposed	2 / 11 (18.18%)	1 / 11 (9.09%)	
occurrences (all)	2	1	
Dizziness			

subjects affected / exposed occurrences (all)	4 / 11 (36.36%) 4	0 / 11 (0.00%) 0	
General disorders and administration site conditions Fatigue subjects affected / exposed occurrences (all)	5 / 11 (45.45%) 5	1 / 11 (9.09%) 1	
Eye disorders Blurred vision subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 11 (0.00%) 0	
Gastrointestinal disorders Nausea subjects affected / exposed occurrences (all) Abdominal gas subjects affected / exposed occurrences (all) Dry mouth subjects affected / exposed occurrences (all) Heartburn subjects affected / exposed occurrences (all) Abdominal pain subjects affected / exposed occurrences (all)	3 / 11 (27.27%) 3 1 / 11 (9.09%) 1 1 / 11 (9.09%) 1 1 / 11 (9.09%) 1 3 / 11 (27.27%) 3	0 / 11 (0.00%) 0 0 / 11 (0.00%) 0 1 / 11 (9.09%) 1 0 / 11 (0.00%) 0 2 / 11 (18.18%) 2	
Endocrine disorders Hyperglycaemia subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 11 (0.00%) 0	
Musculoskeletal and connective tissue disorders Muscle discomfort subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 11 (9.09%) 1	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
17 November 2022	The study design was changed from a parallel design to a cross-over design

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported